This is the latest speculative ASX tech buy from Citigroup

If you are on the hunt for the next shooting star in the small-cap tech sector, Citigroup may have just the trick for you.

| More on:
Investor with palm up and graphic illustration of asx small cap tech shares charts shooting from his hand

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

If you are on the hunt for the next shooting star in the small-cap tech sector, Citigroup may have just the trick for you.

Appetite for such stocks is strong after Brainchip Holdings Ltd (ASX: BRN) share price, Pointerra Ltd (ASX:3DP) share price and Tesserent Ltd (ASX: TNT) shot out the lights in 2020.

These stocks gained more than 700% over the past 12 months when the S&P/ASX 200 Index (Index:^AXJO) is standing at breakeven at best.

Big rewards and risks for this ASX small cap tech stock

If you want big rewards, you have to be prepared to stomach big risks. On that front, Citigroup reckons the Control Bionics Ltd (ASX: CBL) could be worth a punt.

The broker just initiated coverage on the CBL share price and slapped a "speculative buy" recommendation on it.

Control Bionics makes a wearable device that helps the disabled operate and communicate via a computer using only neural or visual signals.

Does CBL have a competitive advantage?

The company's technology, called NeuroNode, has an edge over the competition. Traditional systems use the movement of an arm or finger to activate a keyboard. Other visual/neural devices are harder to use and isn't as flexible.

"CBL has received regulatory clearance for the NeuroNode technology in key regions of US, Australia, Canada and Europe," explained Citi.

"A key target market is Japan and steps are in progress to secure relevant approvals."

Key revenue driver

Another noteworthy point is that Control Bionics is an approved provider under the National Disability Insurance Scheme (NDIS).

It is also approved by the US Veterans' Administration and Medicaid (in most states) as well as relationships with several private payors.

Around 78% of its revenues come from health insurers, according to Citi. That is a good thing as it makes the device accessible to the masses.

What is the CBL share price worth?

Control Bionics raised $15 million from its initial public offer in December last year as it sold shares at 60 cents a piece.

Those who jumped in have plenty to smile about as the CBL share price is currently trading at 97 cents.

But Citi believes it could go a lot higher in 2021 as it has a 12-month price target of $1.42 a share.

This leaves a lot of the profit on the table, but just remember that small cap tech stocks aren't for the fainthearted.

Brendon Lau has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of Pointerra Limited. The Motley Fool Australia owns shares of CBL Limited. The Motley Fool Australia has recommended Pointerra Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Market News

A cute little kid in a suit pulls a shocked face as he talks on his smartphone.
Share Market News

Telstra share price hits 8-year high amid a lacklustre trading week

The ASX 200 communications services sector was the best performer last week, rising 2.96%.

Read more »

share buyers, investors, happy investors
ETFs

How I would build a $100,000 portfolio with ASX ETFs today

You don't need more than three ETFs to build a diversified portfolio...

Read more »

A young man pointing up looking amazed, indicating a surging share price movement for an ASX company
Broker Notes

These ASX 200 shares could rise 20% to 100%

Analysts are expecting these shares to deliver big returns over the next 12 months.

Read more »

Three people in a corporate office pour over a tablet, ready to invest.
Broker Notes

Top brokers name 3 ASX shares to buy next week

Brokers gave buy ratings to these ASX shares last week. Why are they bullish?

Read more »

The silhouettes of ten people holding hands with their arms raised against the sky, as the sun rises or sets in the background.
Share Gainers

Here are the top 10 ASX 200 shares today

ASX shares finished the trading week on a high this Friday.

Read more »

A businessman stacks building blocks.
Technology Shares

6% gain! What's up with Block shares today?

Block shares are up more than 34% since 2 May.

Read more »

Broker looking at the share price.
Broker Notes

Brokers name 3 ASX shares to buy today

Here's why brokers are feeling bullish about these three shares this week.

Read more »

A young man punches the air in delight as he reacts to great news on his mobile phone.
Share Gainers

Why ARB, Block, Mayne Pharma, and Paladin Energy shares are charging higher today

These shares are having a strong finish to the week. But why?

Read more »